PMID- 28467720
OWN - NLM
STAT- MEDLINE
DCOM- 20180131
LR  - 20231213
IS  - 1747-6356 (Electronic)
IS  - 1747-6348 (Linking)
VI  - 11
IP  - 6
DP  - 2017 Jun
TI  - Second-line therapy of squamous non-small cell lung cancer: an evolving 
      landscape.
PG  - 469-479
LID - 10.1080/17476348.2017.1326822 [doi]
AB  - The treatment of lung cancer has radically changed over the last few years. The 
      discovery of druggable oncogenic alterations and the introduction of 
      immunotherapy have provided lung cancer patients with the possibility of more 
      efficient and less toxic therapeutic alternatives than chemotherapy. In the case 
      of lung squamous cell carcinoma (LSCC), the treatment progress is slower than 
      adenocarcinoma, for which several targeted agents have been already approved. The 
      standard first-line therapy for LSCC, in most sites of the world, is 
      platinum-based chemotherapy. After disease progression, these patients now have 
      novel treatment options, including antiangiogenic agents and immune checkpoint 
      blockade. Areas covered: We provide a summary of the recent novelties for the 
      second-line therapy of LSCC, emphasizing on the results of the most important 
      clinical trials that have led to regulatory approvals. Expert commentary: Immune 
      checkpoint inhibitors have changed the therapeutic algorithm for LSCC patients. 
      Other treatment options in the second-line setting include ramucirumab in 
      combination with docetaxel and afatinib. However, we still lack biomarkers to 
      predict which patients could respond better to each treatment. Despite the 
      identification of several actionable molecular alterations, there are no approved 
      targeted agents specific for advanced LSCC. Results from ongoing biomarker-driven 
      studies are eagerly awaited to establish effective treatments for molecularly 
      selected subgroups of patients.
FAU - Lazzari, Chiara
AU  - Lazzari C
AD  - a Department of Oncology, Division of Experimental Medicine , IRCCS San Raffaele 
      , Milan , Italy.
FAU - Karachaliou, Niki
AU  - Karachaliou N
AD  - b Medical Oncology Department , Institute of Oncology Rosell (IOR), University 
      Hospital Sagrat Cor , Barcelona , Spain.
FAU - Gregorc, Vanesa
AU  - Gregorc V
AD  - a Department of Oncology, Division of Experimental Medicine , IRCCS San Raffaele 
      , Milan , Italy.
FAU - Bulotta, Alessandra
AU  - Bulotta A
AD  - a Department of Oncology, Division of Experimental Medicine , IRCCS San Raffaele 
      , Milan , Italy.
FAU - Gonzalez-Cao, Maria
AU  - Gonzalez-Cao M
AD  - c Translational Cancer Research Unit, Instituto Oncologico Dr Rosell , Dexeus 
      University Hospital-Quironsalud Group , Barcelona , Spain.
FAU - Verlicchi, Alberto
AU  - Verlicchi A
AD  - d S.C. Oncologia , Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.
FAU - Altavilla, Giuseppe
AU  - Altavilla G
AD  - e Medical Oncology Unit, Department of Human Pathology "G. Barresi" , University 
      of Messina , Messina , Italy.
FAU - Rosell, Rafael
AU  - Rosell R
AD  - c Translational Cancer Research Unit, Instituto Oncologico Dr Rosell , Dexeus 
      University Hospital-Quironsalud Group , Barcelona , Spain.
AD  - f Germans Trias i Pujol Research Institute , Badalona , Spain.
AD  - g Catalan Institute of Oncology , Germans Trias i Pujol University Hospital , 
      Badalona , Spain.
FAU - Santarpia, Mariacarmela
AU  - Santarpia M
AD  - e Medical Oncology Unit, Department of Human Pathology "G. Barresi" , University 
      of Messina , Messina , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170515
PL  - England
TA  - Expert Rev Respir Med
JT  - Expert review of respiratory medicine
JID - 101278196
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Quinazolines)
RN  - 0 (Radiation-Sensitizing Agents)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - 41UD74L59M (Afatinib)
SB  - IM
MH  - Afatinib
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Carcinoma, Squamous Cell/*drug therapy/pathology
MH  - Docetaxel
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Quinazolines/therapeutic use
MH  - Radiation-Sensitizing Agents/*therapeutic use
MH  - Retreatment
MH  - Taxoids/therapeutic use
MH  - Ramucirumab
OTO - NOTNLM
OT  - Lung Squamous Cell Carcinoma (LSCC)
OT  - antiangiogenic agents
OT  - immune checkpoint inhibitors
OT  - immunotherapy
OT  - targeted therapies
EDAT- 2017/05/04 06:00
MHDA- 2018/02/01 06:00
CRDT- 2017/05/04 06:00
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2018/02/01 06:00 [medline]
PHST- 2017/05/04 06:00 [entrez]
AID - 10.1080/17476348.2017.1326822 [doi]
PST - ppublish
SO  - Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: 
      10.1080/17476348.2017.1326822. Epub 2017 May 15.